Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) is -38.61% lower on its value in year-to-date trading and has touched a low of $29.17 and a high of $62.53 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CRNX stock was last observed hovering at around $30.62 in the last trading session, with the day’s gains setting it 0.77%.
Currently trading at $31.39, the stock is -8.19% and -12.08% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.16 million and changing 2.51% at the moment leaves the stock -34.80% off its SMA200. CRNX registered -32.54% loss for a year compared to 6-month loss of -38.57%. The firm has a 50-day simple moving average (SMA 50) of $35.704 and a 200-day simple moving average (SMA200) of $48.1466.
The stock witnessed a -7.84% gain in the last 1 month and extending the period to 3 months gives it a -38.05%, and is -9.04% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.05% over the week and 5.03% over the month.
Crinetics Pharmaceuticals Inc (CRNX) has around 437 employees, a market worth around $2.92B and $0.00M in sales. Distance from 52-week low is 7.59% and -49.80% from its 52-week high. The company has generated returns on investments over the last 12 months (-21.79%).
with sales reaching $100k over the same period.The EPS is expected to shrink by -10.98% this year, but quarterly earnings will post 483.82% year-over-year. Quarterly sales are estimated to shrink -84.38% in year-over-year returns.
350.0 institutions hold shares in Crinetics Pharmaceuticals Inc (CRNX), with institutional investors hold 112.94% of the company’s shares. The shares outstanding are 92.93M, and float is at 86.62M with Short Float at 8.97%. Institutions hold 110.62% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 6.23 million shares valued at $279.06 million. The investor’s holdings represent 7.8857 of the CRNX Shares outstanding. As of 2024-06-30, the second largest holder is DRIEHAUS CAPITAL MANAGEMENT LLC with 6.11 million shares valued at $273.76 million to account for 7.7361 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 4.51 million shares representing 6.245 and valued at over $202.2 million, while WELLINGTON MANAGEMENT GROUP LLP holds 5.848 of the shares totaling 4.62 million with a market value of $206.95 million.
Crinetics Pharmaceuticals Inc (CRNX) Insider Activity
The most recent transaction is an insider sale by Pizzuti Dana, the company’s Chief Med and Dev Officer. SEC filings show that Pizzuti Dana sold 2,515 shares of the company’s common stock on Mar 19 ’25 at a price of $34.20 per share for a total of $86021.0. Following the sale, the insider now owns 72233.0 shares.
Crinetics Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 19 ’25 that Knight Jeff E. (Chief Operating Officer) sold a total of 7,162 shares of the company’s common stock. The trade occurred on Mar 19 ’25 and was made at $34.20 per share for $0.24 million. Following the transaction, the insider now directly holds 87491.0 shares of the CRNX stock.
Still, SEC filings show that on Mar 19 ’25, Betz Stephen F. (Chief Scientific Officer) disposed off 5,770 shares at an average price of $34.20 for $0.2 million. The insider now directly holds 108,588 shares of Crinetics Pharmaceuticals Inc (CRNX).
